NATCOPHARM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.3
| Stock Code | NATCOPHARM | Market Cap | 20,991 Cr. | Current Price | 1,170 ₹ | High / Low | 1,227 ₹ |
| Stock P/E | 14.0 | Book Value | 462 ₹ | Dividend Yield | 0.51 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,083 ₹ | DMA 200 | 976 ₹ |
| Chg in FII Hold | 2.21 % | Chg in DII Hold | 0.07 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 58.1 | MACD | 28.8 | Volume | 2,44,406 | Avg Vol 1Wk | 4,90,812 |
| Low price | 789 ₹ | High price | 1,227 ₹ | PEG Ratio | 0.09 | Debt to equity | 0.03 |
| 52w Index | 87.1 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 30.5 |
📊 Financials: The company demonstrates strong profitability with ROE at 27.5% and ROCE at 31.8%, reflecting efficient capital usage. Debt-to-equity is very low at 0.03, showing a near debt-free balance sheet. Quarterly PAT dropped from ₹501 Cr. to ₹107 Cr., a -14.4% variation, indicating earnings volatility. EPS of ₹83.8 supports solid cash flow generation.
💹 Valuation: Current P/E of 14.0 is well below the industry average of 30.5, suggesting undervaluation. The PEG ratio of 0.09 highlights highly attractive growth prospects relative to price. Book value of ₹462 against a market price of ₹1,170 implies a reasonable P/B ratio. Intrinsic value appears supportive of current levels, making the stock appealing for accumulation.
🏭 Business Model: The company operates in pharmaceuticals, benefiting from strong R&D, niche product portfolio, and global market presence. Competitive advantage lies in cost efficiency, intellectual property, and ability to deliver specialized drugs.
📈 Entry Zone: A favorable entry would be closer to ₹1,100–1,150, near the 50 DMA of ₹1,083. Current price of ₹1,170 is slightly above fair value, making gradual accumulation attractive.
⏳ Long-Term Holding: Strong fundamentals, low debt, and undervaluation relative to peers support long-term holding. Investors can accumulate steadily, with potential for strong returns as pharmaceutical demand remains resilient globally.
Positive
- ✅ Strong ROE (27.5%) and ROCE (31.8%)
- ✅ Very low debt-to-equity ratio (0.03)
- ✅ P/E (14.0) below industry average, suggesting undervaluation
- ✅ FII holdings increased (+2.21%) showing foreign investor confidence
Limitation
- ⚠️ Quarterly PAT decline (-14.4%) indicates earnings volatility
- ⚠️ Dividend yield of 0.51% is modest
- ⚠️ RSI at 58.1 suggests neutral momentum
Company Negative News
- 📉 PAT dropped from ₹501 Cr. to ₹107 Cr. quarter-on-quarter
Company Positive News
- 📈 Increase in FII holding (+2.21%) reflects strong foreign investor interest
- 📈 DII holding also increased slightly (+0.07%)
Industry
- 💊 Pharmaceutical sector benefits from global healthcare demand
- 📊 Industry P/E at 30.5 suggests peers are valued higher
- 🌍 Growth opportunities in generics, specialty drugs, and exports
Conclusion
Overall, the company is financially strong with excellent return ratios, low debt, and undervaluation compared to peers. Despite recent earnings volatility, fundamentals remain solid. Best strategy is gradual accumulation near ₹1,100–1,150 for long-term holding, with potential for strong returns as pharmaceutical demand continues to grow.
Would you like me to extend this with a peer comparison against other pharma companies, or a technical analysis view to highlight support/resistance and momentum indicators?